During the recent session, TransCode Therapeutics Inc (NASDAQ:RNAZ)’s traded shares were 0.49 million, with the beta value of the company hitting 1.14. At the last check today, the stock’s price was $1.72, reflecting an intraday loss of -6.28% or -$0.11. The 52-week high for the RNAZ share is $66.33, that puts it down -3756.4 from that peak though still a striking -0.58% loss since the share price plummeted to a 52-week low of $1.73. The company’s market capitalization is $1.19M, and the average trade volume was 1.84 million shares over the past three months.
TransCode Therapeutics Inc (NASDAQ:RNAZ) trade information
TransCode Therapeutics Inc (RNAZ) registered a -6.28% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.28% in intraday trading to $1.72, hitting a weekly high. The stock’s 5-day price performance is -31.94%, and it has moved by -72.16% in 30 days. Based on these gigs, the overall price performance for the year is -92.58%.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 300k as predicted by 1 analyst(s).
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -28.81%. While earnings are projected to return 95.41% in 2025, the next five years will return 78.85% per annum.
RNAZ Dividends
TransCode Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
TransCode Therapeutics Inc (NASDAQ:RNAZ)’s Major holders
Also, the Mutual Funds coming in first place with the largest holdings of TransCode Therapeutics Inc (RNAZ) shares are Fidelity Extended Market Index Fund and Fidelity Total Market Index Fund. Data provided on Dec 31, 2024 indicates that Fidelity Extended Market Index Fund owns about 2.86 shares. This amounts to just over 0.41 percent of the company’s overall shares, with a $4954.0 market value. The same data shows that the other fund manager holds slightly less at 1.18, or about 0.17% of the stock, which is worth about $2039.0.
